# A Phase 1 Study of UB-VV500 With Rapamycin in Relapsed/Refractory Multiple Myeloma

> clinical trial · VERIFIED · 2026-07-30

Status: NOT_YET_RECRUITING · Sponsor: Umoja Biopharma · Condition: Multiple Myeloma in Relapse

- Company: Umoja Biopharma
- Sector: Multiple Myeloma in Relapse
- Primary source: https://clinicaltrials.gov/study/NCT07735546

---
Source: MedFuel Intel news monitor. Verification tier: VERIFIED. Informational only, not investment advice. Corrections: media@medfuelinc.com.